Skip to main content

A hematology clinical trial - ALC8

Testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia
Disease Site
Hematologic Clinical Trials
Trial Code
ALC.8 (MM1YA-S01) ǀ NCT05554406
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to compare the usual treatment for high-risk acute myeloid leukemia (AML) with four different combinations of treatment.

This trial is part of a larger research study called myeloMATCH which uses biomarker testing to match people to a clinical trial for AML treatment. Find out more >

Why is this study important?

Treatment plans for AML often involve several phases. This study looks at new treatment options that are being developed for people with high-risk AML in their first phase of treatment. These new treatment options could improve the success of further phases of treatment, but it is not clear if they offer better results than the usual treatment.

Who can participate in this study?

This trial is for:

  • People with previously untreated high-risk AML
  • People aged 18-59 years

This trial is not for:

  • People who have already started treatment for AML
  • People who are pregnant
What are the risks?
  • If you choose to take part in this study, there is a risk that the study approach may not be as good as the usual treatment. There is also a risk that you could have side effects from the study drugs. Some of the most common side effects that the study doctors know about are: decrease in the number of red or white blood cells and platelets, constipation, diarrhea, nausea and vomiting, tiredness or fever. You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of five groups and you will receive either the usual treatment or one of four study treatments. Depending on which group you are placed in, you will also be asked to complete a diary to record the number of pills you take.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The ALC.8 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit https://clinicaltrials.gov/study/NCT05554406.

Use this trial information for your conversation with your health care team

Participating centres

Information coming soon.